Enhanced antitumoral effectiveness of idiotype vaccination induced by the administration of Flt3 ligand combined with interleukin 2 against a murine myeloma

British Journal of Haematology

Volumn 117, Issue 1, 2002, Pages 93-102

  Zeis, Matthias ^a   Zunkel, Tim ^a   Steinmann, Jörg ^a   Schmitz, Norbert ^a   Uharek, Lutz ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Flt3 ligand; Idiotype vaccination; Myeloma

Indexed keywords

FLT3 LIGAND; IMMUNOGLOBULIN IDIOTYPE; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; IMMUNE RESPONSE; INOCULATION; MOUSE; MOUSE STRAIN; MYELOMA; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR REJECTION; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CYTOTOXICITY TESTS, IMMUNOLOGIC; DENDRITIC CELLS; IMMUNOGLOBULIN IDIOTYPES; IMMUNOTHERAPY; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-2; KILLER CELLS, NATURAL; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MODELS, ANIMAL; MULTIPLE MYELOMA; SPLEEN;

EID: 0036227434     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03379.x     Document Type: Article

References (34)

1. Multiple myeloma
2. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony stimulating factor against lymphoma
3. Idiotypic vaccination in B-cell malignancies
4. Naive CD4+ T cells confer idiotype-specific tumor resistance in the absence of antibodies
5. Hematologic effects of Flt3-ligand in vivo in mice
6. In vitro growth inhibition of broad spectrum of tumor cell lines by activated human dendritic cells
7. Flt3-ligand induces transient tumor regression in an ectopic treatment model of major histocompatibility complex-negative prostate cancer
8. Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma
9. Flt3-ligand administration inhibits tumor growth in murine melanoma and lymphoma
10. Murine dendritic cells pulsed in vitro with tumour antigen induce tumour resistance in vivo
11. Rat spleen dendritic cells express natural killer cell receptor protein 1 (NKR-P1) and have cytotoxic activity to select targets via a Ca2+ dependent mechanism
12. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response
13. Liposomal formulation of a self lymphoma antigen induces potent protective antitumor immunity
14. Tumor-specific recognition of human myeloma cells by idiotype-induced CD8+ T cells
15. FLT3-ligand induces tumor regression and antitumor immune response in vivo
16. Myeloma proteins as tumor-specific transplantation antigens
17. Generating a T cell tumor-specific immune response in vivo: Can Flt3-ligand-generated dendritic cells tip the balance?
18. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3-ligand-treated mice: Multiple dendritic subpopulations identified
19. In vivo generation of human dendritic cell subsets by Flt3 ligand
20. Idiotype vaccination in human myeloma: Generation of tumor-specific immune responses after high-dose chemotherapy
21. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic anti-tumor immunity
22. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses
23. In vitro tumor-pulsed or in vivo Flt3 ligand-generated dendritic cells provide protection against acute myelogenous leukemia in nontransplanted or syngeneic bone marrow-transplanted mice
24. Flt3-ligand administration inhibits liver metastases: Role of NK cells
25. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - A feasibility study
26. Systemic administration of interleukin-2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines
27. Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins
28. Dendritic cell vaccines for cancer immunotherapy
29. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine
30. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: Immunological and clinical aspects
31. Antileukemic activity of Flt3-ligand in murine leukemia
32. Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma
33. Idiotype-specific cytotoxic T lymphocytes in multiple myeloma. Evidence for their capacity to lyse autologous primary tumor cells
34. Transfer of idiotypic protein primed allogeneic marrow grafts elicits potent Graft-versus-Myeloma effects in mice